Abstract
Since the discovery of tumor necrosis factor (TNF)-alpha, researchers have pursued many approaches to harness the potency of TNF-alpha and TNF superfamily members to treat human cancers. Several ligands of the TNF superfamily, including TNF-alpha, lymphotoxin, FAS ligand (FasL), and APO2 ligand/TNF-related apoptosis-inducing ligand (Apo2L/TRAIL) have been tested in various stages of clinical research for their anti-tumor efficacy. Moreover, several antibodies to TNF receptor (TNFR) superfamily members are now being explored as cancer therapeutics. Due to the toxicity associated with delivering TNF-alpha systemically at clinically relevant doses, more targeted methods are now seen as a likely alternative to provide a localized therapeutically effective dose of TNF-alpha. In this review we revisit historical attempts to use TNF-alpha to treat human cancer, and put this into the context of more recent targeted strategies to circumvent TNF-alphas systemic toxicity. We will attempt to integrate the results of pre-clinical and clinical trials with a concise synopsis of the TNF-alpha signaling network, with the goal of reconciling our understanding of how the cell biology and tumor biology mechanistically relate.
Current Cancer Drug Targets
Title: Tumor Necrosis Factor: Renaissance as a Cancer Therapeutic?
Volume: 8 Issue: 2
Author(s): D. Daniel and N. S. Wilson
Affiliation:
Abstract: Since the discovery of tumor necrosis factor (TNF)-alpha, researchers have pursued many approaches to harness the potency of TNF-alpha and TNF superfamily members to treat human cancers. Several ligands of the TNF superfamily, including TNF-alpha, lymphotoxin, FAS ligand (FasL), and APO2 ligand/TNF-related apoptosis-inducing ligand (Apo2L/TRAIL) have been tested in various stages of clinical research for their anti-tumor efficacy. Moreover, several antibodies to TNF receptor (TNFR) superfamily members are now being explored as cancer therapeutics. Due to the toxicity associated with delivering TNF-alpha systemically at clinically relevant doses, more targeted methods are now seen as a likely alternative to provide a localized therapeutically effective dose of TNF-alpha. In this review we revisit historical attempts to use TNF-alpha to treat human cancer, and put this into the context of more recent targeted strategies to circumvent TNF-alphas systemic toxicity. We will attempt to integrate the results of pre-clinical and clinical trials with a concise synopsis of the TNF-alpha signaling network, with the goal of reconciling our understanding of how the cell biology and tumor biology mechanistically relate.
Export Options
About this article
Cite this article as:
Daniel D. and Wilson S. N., Tumor Necrosis Factor: Renaissance as a Cancer Therapeutic?, Current Cancer Drug Targets 2008; 8 (2) . https://dx.doi.org/10.2174/156800908783769346
DOI https://dx.doi.org/10.2174/156800908783769346 |
Print ISSN 1568-0096 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5576 |
Call for Papers in Thematic Issues
Advances in Cancer Biomarkers and Potential Drug Targets: From Diagnosis to Therapy
Cancer biomarkers play a crucial role in the diagnosis, prognosis, and treatment of cancer. They provide valuable information for cancer detection, risk assessment, treatment selection, and monitoring response to therapy. With advancements in molecular biology and high-throughput technologies, there has been an increasing interest in identifying and characterizing cancer biomarkers ...read more
Novel Therapeutic Approaches to Target Drug Resistant Tumors
With the development of disciplines such as chemical biology and molecular biology, the genes or proteins closely related to tumor occurrence and development have gradually become clear. Targeted therapies targeting these genes or proteins provide more effective methods for tumor treatment. Tumor targeted drugs generally only act on specific targets ...read more
ROLE OF IMMUNE AND GENOTOXIC RESPONSE BIOMARKERS IN TUMOR MICROENVIRONMENT IN CANCER DIAGNOSIS AND TREATMENT
Biological biomarkers have been used in medical research as an indicator of a normal or abnormal process inside the body, or of a disease. Nowadays, various researchers are in process to explore and investigate the biological markers for the early assessment of cancer. DNA Damage response (DDR) pathways and immune ...read more
Targeting the battlefield between host and tumor: basic research and clinical practice on reshaping tumor immune microenvironment
Immune system protects host against malignant tumors through effector cells and molecules. Cancer development and its response to therapy are regulated by inflammation, which either promotes or suppresses cancer progression. Chronic inflammation facilitates cancer progression and treatment resistance, whereas induction of acute inflammatory reactions often lead to anti-cancer immune responses. ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Alpha-2 Agonists: Can they Modify the Outcomes in the Postanesthesia Care Unit?
Current Drug Targets Synthesis and DPPH Radical Scavenging Activity of 5-Arylidene-N,Ndimethylbarbiturates
Medicinal Chemistry Classical and New Renin-Angiotensin Signalling in Atherosclerosis
Current Signal Transduction Therapy Phenothiazines as Anti-Multi-Drug Resistant Tubercular Agents
Infectious Disorders - Drug Targets Therapeutic Perspectives of Inhibitors of Endocannabinoid Degradation
Current Drug Targets - CNS & Neurological Disorders Pharmacological Treatment of Hypertension in Pregnancy
Current Pharmaceutical Design Developing Specific Therapeutic Strategies for Transfusion-Related Acute Lung Injury. An Overview of Potentially Useful Animal Models
Cardiovascular & Hematological Agents in Medicinal Chemistry Adrenal Insufficiency in Sepsis
Current Pharmaceutical Design Albumin Infusion Therapy in Stroke, Sepsis and the Critically Ill
Current Nutrition & Food Science Neuropeptide Systems and Schizophrenia
CNS & Neurological Disorders - Drug Targets Relative Survival Benefit and Morbidity with Fluids in Severe Sepsis - A Network Meta-Analysis of Alternative Therapies
Current Drug Safety Scintigraphic Imaging of Inflammatory Processes
Current Medicinal Chemistry - Anti-Inflammatory & Anti-Allergy Agents Adenosine Receptor Ligands in Clinical Trials
Current Topics in Medicinal Chemistry Bioactive Cyclohexenones: A Mini Review
Current Bioactive Compounds Disulfiram: An Old Therapeutic with New Applications
CNS & Neurological Disorders - Drug Targets Novel Antiinflammatory and Antiinfective Agents
Anti-Infective Agents in Medicinal Chemistry Vasopressin in Liver Disease – Should We Turn On or Off?
Current Clinical Pharmacology Chronic Kidney Disease and Thrombosis
Current Pediatric Reviews Toll-Like Receptors: Link between “Danger” Ligands and Plaque Instability
Current Drug Targets Endocannabinoid Signaling in the Etiology and Treatment of Major Depressive Illness
Current Pharmaceutical Design